BUSINESS
Fujifilm, BlueRock Form Strategic Alliance to Develop iPSC Therapies for Ocular Diseases
Fujifilm Holdings said on May 18 that its group companies Fujifilm Cellular Dynamics and Opsis Therapeutics have entered into a strategic R&D alliance with BlueRock Therapeutics, a Bayer subsidiary, to develop treatments for ocular diseases using iPS cells. Under their…
To read the full story
Related Article
- BlueRock In-Licenses Fujifilm’s iPSC Therapy for Ocular Disease
January 25, 2024
BUSINESS
- Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
- Gilead Files Trodelvy-Keytruda Combo for 1L TNBC in Japan
April 24, 2026
- Co-Promotions Dominate in Oncology, Diabetes Alliances: Fuji Keizai
April 24, 2026
- Medii, Pediatric Neurology Society Build System to Support Elevidys Use
April 24, 2026
- Oncolys’ OBP-301 Wins US Fast Track Designation
April 24, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





